



**Abstract Type : Poster exhibition**

**Abstract Submission No.: A-0292**

**Abstract Topic : Renal Conservative Care + Geriatric Nephrology + Sarcopenia**

### **Nutritional Frailty and Its Association with Renal Function Change in Elderly CKD Patients on SGLT2 Inhibitors**

**Jwa Kyung Kim**, Sei Hong Min, Insoo Kim, Sung Gyun Kim, Jungnam An, Hyung-Seok Lee  
Department of Internal Medicine, Hallym University Sacred Heart Hospital, Korea, Republic of

**Objectives :** Chronic kidney disease (CKD) is common in the elderly, and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are now first-line therapy due to their nephroprotective and cardiovascular benefits. While generally safe, caution is required in elderly patients with comorbidities such as low body mass index (BMI), or a high risk of volume depletion. This study evaluates the impact of nutritional status on changes in renal function in elderly CKD patients treated with SGLT2i.

**Methods :** We analyzed real-world data from 302 elderly CKD patients who were newly prescribed SGLT2i, with renal function measurements at baseline, 3 months, and 12 months. Nutritional status was assessed using the Geriatric Nutritional Index (GNRI), with scores  $\leq 98$  indicating nutritional frailty. Rapid renal progression was defined as an eGFR decline  $>10$  ml/min/1.73m<sup>2</sup> or  $\geq 40\%$  reduction within a year.

**Results :** The mean age was  $76.0 \pm 8.1$  years, with 81.5% diabetes. Among them, 46 patients (15%) had a low GNRI score ( $\leq 98$ ). These patients were older (80.5 vs. 75.2 years,  $P < 0.001$ ) and had significantly lower BMI, body weight, hemoglobin, and albumin levels ( $P < 0.001$ ). They also exhibited higher rates of proteinuria with increased protein/creatinine ratios ( $P < 0.001$ ). Over 12 months, the GNRI  $\leq 98$  group experienced greater eGFR declines compared to the GNRI  $> 98$  group ( $-3.5$  vs.  $-1.7$  ml/min/1.73m<sup>2</sup>,  $P < 0.001$ ). Low GNRI score was also independently associated with a higher risk of rapid renal progression, with a multivariate hazard ratio of 3.05 (95% CI: 1.20–7.60,  $P = 0.016$ ) after adjusting for age, anemia, and proteinuria.

**Conclusions :** SGLT2i is generally safe and effective in most elderly CKD patients, as shown by stable eGFR changes in the GNRI  $> 98$  group. However, patients with a low GNRI score face a higher risk of rapid renal progression, suggesting the need to assess frailty and nutritional status when prescribing SGLT2i in vulnerable elderly CKD population.

그림 1.jpg

